Actively Recruiting
Evaluating AZD2265 Versus Standard Treatments in Men with PSMA-positive Metastatic Castration-resistant Prostate Cancer VECTRA-01
Led by AstraZeneca · Updated on 2026-10-19
670
Participants Needed
151
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of AZD2265 compared to standard treatments in men with PSMA-positive metastatic castration-resistant prostate cancer mCRPC. The study aims to show whether AZD2265 can improve radiographic progression-free survival and overall survival. This phase III trial involves about 670 adult male participants and is sponsored by AstraZeneca. Participants will be randomly assigned to receive either AZD2265 or a standard care treatment chosen by the investigator, which may include cabazitaxel, androgen receptor pathway inhibitors ARPI, or radium-223. Treatments will continue until the disease progresses, unacceptable side effects occur, or other reasons for stopping arise. Tumor scans will continue after treatment ends until confirmed progression or death. Throughout the study, participants will be monitored with imaging scans and laboratory tests to assess disease progression and response to treatment. Researchers will track multiple outcomes such as progression-free survival, PSA reductions, response rates, and symptomatic skeletal events for up to approximately 33 months. Safety and scientific integrity will be overseen by an independent committee, and participants will be followed for survival until the studys completion.
CONDITIONS
Brief Title
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here